Alerts will be sent to your verified email
Verify Email
BACPHAR
|
Bacil Pharma
|
ANG Lifesciences
|
Kabra Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.32 % | 12.03 % | 36.01 % |
|
5yr average Equity Multiplier
|
1.36 | 3.3 | -0.87 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.77 | 0.0 |
|
5yr Avg Net Profit Margin
|
0.0 | -2.26 % | 0.0 |
|
Price to Book
|
2.3 | 1.06 | 1.96 |
|
P/E
|
36.69 | 0.0 | 11.63 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 70.26 Days | 0.0 |
|
Inventory Days
|
0.0 | 107.37 Days | 0.0 |
|
Days Receivable
|
0.0 | 274.82 Days | 0.0 |
|
Days Payable
|
0.0 | 235.98 Days | 0.0 |
|
5yr Average Interest Coverage Ratio
|
-943.72 | 1.81 | -1068.45 |
|
5yr Avg ROCE
|
-75.56 % | 15.08 % | 21.53 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 7.68 % | 0.0 |
|
5 yr average Debt to Equity
|
0.05 | 0.97 | -1.45 |
|
5yr CAGR Net Profit
|
n/a | n/a | 43.36 % |
|
5yr Average Return on Assets
|
-70.2 % | 1.04 % | -21.34 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 70.6 % | 0.0 |
|
Share Pledged by Promoters
|
0.0 | 44.88 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-42.67 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bacil Pharma
|
ANG Lifesciences
|
Kabra Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|